Health AI Central
Share:
Peer-Reviewed Publication
Int J Med Inform2024;191105584.November 1, 2024Journal Article

The potential for drug incompatibility and its drivers - A hospital wide retrospective descriptive study.

Nahyun Keum1, Junsang Yoo2, Sujeong Hur1, Soo-Yong Shin2, Patricia C Dykes3, Min-Jeoung Kang3, Yong Seok Lee4, Won Chul Cha5
1Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea; AvoMD, Seoul, Republic of Korea.
2Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea.
3Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
4Department of Pharmaceutical Services, Samsung Medical Center, Seoul, Republic of Korea.
5Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea; Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Digital Innovation Center, Samsung Medical Center, Seoul, Republic of Korea. Electronic address: wc.cha@samsung.com.
PubMed DOI

Abstract

OBJECTIVE: Drug incompatibility, a significant subset of medication errors, threaten patient safety during the medication administration phase. Despite the undeniably high prevalence of drug incompatibility, it is currently poorly understood because previous studies are focused predominantly on intensive care unit (ICU) settings. To enhance patient safety, it is crucial to expand our understanding…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.